Graftys Announces The Extension Of Its CE Mark For Its Calcium Phosphate Cements To Now Include GRAFTYS HBS And GRAFTYS Quickset For The Indication Of Subchondral Bone Marrow Lesions Around The Knee Joint (BML)

AIX-EN-PROVENCE, France--(BUSINESS WIRE)--GRAFTYS SA, a company focused on development and commercialization of orthopedic biomaterials, is pleased to announce that it has obtained authorization from its notified body, NSAI (National Standards Authority of Ireland) for European commercialization for two of its cements (GRAFTYS® HBS and GRAFTYS® Quickset) for treatment of bone marrow lesions caused by traumatic injury.

Help employers find you! Check out all the jobs and post your resume.